Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma

• KAMEOKA Yoshihiro

  Department of Hematology, Akita University Graduate School of Medicine

• TAKAHASHI Naoto

  Department of Hematology, Akita University Graduate School of Medicine

• ISHIZAWA Kenichi

  Hematology and Rheumatology, Tohoku University Graduate School of Medicine

• KATO Yuichi

  3rd Department of Internal Medicine, Yamagata University

• ITO Jugo

  Department of Oncology, Hirosaki University

• SASAKI Osamu

  Division of Hematology, Miyagi Cancer Center

• MURAI Kazunori

  School of Medical Hematology and Oncology, Iwate Medical University

• NOJI Hideyoshi

  Department of Cardiology and Hematology, Fukushima Medical University

• HIROKAWA Makoto

  School of Medicine, Akita University

• TAJIMA Katsusi

  3rd Department of Internal Medicine, Yamagata University

• SHICHISHIMA Tsutomu

  Department of Cardiology and Hematology, Fukushima Medical University

• ISHIDA Yoji

  School of Medical Hematology and Oncology, Iwate Medical University

• HARIGAE Hideo

  Hematology and Rheumatology, Tohoku University Graduate School of Medicine

• SAWADA Kenichi

  Department of Hematology, Akita University Graduate School of Medicine

収録刊行物

• International journal of hematology

  International journal of hematology 96 (5), 624-630, 2012-11-01

キーワード

• MCVC
• Malignant lymphoma
• Auto-SCT
• Feasibility
• Safety

詳細情報

• CRID: 1571417126119918464
• NII論文ID: 10031126760
• NII書誌ID: AA10797094
• ISSN: 09255710
• Web Site: https://search.jamas.or.jp/link/ui/2014009987
• 本文言語コード: en
• データソース種別:
  • CiNii Articles